$NAMS SEC Filings

Filed On	Filing
02 Oct 2026	Form 4: Kastelein Johannes Jacob Pieter, Director Received 50,246 shares by exercise or conversion · Sold 50,246 shares ($1.26M)
29 Sep 2026	8-K: Other Events NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease
22 Sep 2026	SCHEDULE 13D/A
21 Sep 2026	8-K: Other Events On September 21, 2026, NewAmsterdam Pharma Company N.V. (the “Company”) along with its partner Menarini Group (“Menarini”) announced that the European Commission (“EC”) has granted marketing authorization for Ubeslo® (obicetrapib 10 mg m...
15 Sep 2026	Form 4: Davidson Michael H., Director Bought 10,000 shares ($227K)
09 Sep 2026	Form 4: Smither John W, Director Sold 1,600 shares ($40.5K)
03 Sep 2026	Form 4: Gunning Robert William, Vice President, Controller Received 3,200 shares as a grant or award · Granted 14,000 Option (right to buy)
25 Aug 2026	144/A
25 Aug 2026	Form 4: Kastelein Johannes Jacob Pieter, Director Received 125,000 shares by exercise or conversion · Sold 125,000 shares ($3.36M)
24 Aug 2026	144
14 Aug 2026	Form 3: Gunning Robert William, Vice President, Controller No securities owned
14 Aug 2026	8-K/A: Departure/Election of Directors or Officers; Compensation Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
14 Aug 2026	8-K: Departure/Election of Directors or Officers; Compensation
06 Aug 2026	SCHEDULE 13G/A
05 Aug 2026	10-Q
05 Aug 2026	8-K: Results of Operations and Financial Condition
24 Jul 2026	8-K: Other Events
22 Jul 2026	Form 4: Kooij Louise Frederika, Chief Accounting Officer Received 105,000 shares by exercise or conversion ($1.19M) · Sold 105,000 shares ($3.19M)
22 Jul 2026	8-K: Departure/Election of Directors or Officers; Compensation
24 Jun 2026	Form 4: Kooij Louise Frederika, Chief Accounting Officer Received 40,000 shares by exercise or conversion ($451K) · Sold 40,000 shares ($1.21M)

Comments